Cisapride use during human pregnancy - A prospective, controlled multicenter study

被引:23
作者
Bailey, B
Addis, A
Lee, A
Sanghvi, K
Mastroiacovo, P
Mazzone, T
Bonati, M
Paolini, C
Garbis, H
Val, T
DeSouza, CFM
Matsui, D
Schechtman, AS
Conover, B
Lau, M
Koren, G
机构
[1] HOSP SICK CHILDREN,DIV CLIN PHARMACOL & TOXICOL,DEPT PEDIAT,MOTHERISK PROGRAM,TORONTO,ON M5G 1X8,CANADA
[2] UNIV TORONTO,TORONTO,ON,CANADA
[3] TELEFONO ROSSO,ROME,ITALY
[4] CTR REG INFORMAZ FARM,MILAN,ITALY
[5] CLIN OSTETR & GINECOL,MILAN,ITALY
[6] TERATOL INFORMAT SERV,BILTHOVEN,NETHERLANDS
[7] SERV PHARMACOTOXIVIGILANCE,LYON,FRANCE
[8] CTR ANTIPOISONS,LYON,FRANCE
[9] SERV INFORMACAE SOBRE AGENTES TERATOGEN,PORTO ALEGRE,RS,BRAZIL
[10] FOETAL RISK ASSESSMENT MATERNAL EXPOSURE,LONDON,ON,CANADA
[11] ILLINOIS TERATOGEN INFORMAT SERV,CHICAGO,IL
[12] NEBRASKA TERATOGEN PROJECT,OMAHA,NE
关键词
cisapride; pregnancy; drug-induced abnormality; human;
D O I
10.1023/A:1018898707449
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The objective of this prospective multicenter study was to determine whether cisapride is associated with increased risk of malformations, spontaneous abortions, or decreased birthweight when used during pregnancy. Cases were paired for age, smoking, and alcohol consumption with controls exposed to nonteratogens, as well as with disease-paired controls. One hundred and twenty-nine pregnant women were exposed to cisapride during pregnancy, including 88 during the period of fetal organogenesis, There were no differences in maternal history, birthweight, gestational age at delivery, and rates of livebirths, spontaneous or therapeutic abortions, fetal distress, and major or minor malformations among groups, It is concluded that exposure to cisapride during pregnancy is not associated with a major increased risk of malformations or spontaneous abortions or with decreased birthweight.
引用
收藏
页码:1848 / 1852
页数:5
相关论文
共 17 条
[1]  
*AB CONC, 1988, STATV SE PLUS GRAPH
[2]   CISAPRIDE - A GASTROINTESTINAL PROKINETIC DRUG [J].
BARONE, JA ;
JESSEN, LM ;
COLAIZZI, JL ;
BIERMAN, RH .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (04) :488-500
[3]   HOW SAFE AND ACCEPTABLE IS CISAPRIDE [J].
BENNETT, JR .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :59-61
[4]  
BRUTON LL, 1996, GOODMAN GILMANS PHAR, P933
[5]  
EVERSON GT, 1992, GASTROENTEROL CLIN N, V21, P751
[6]   Safety of first trimester exposure to histamine H-2 blockers - A prospective cohort study [J].
Magee, LA ;
Inocencion, G ;
Kamboj, L ;
Rosetti, F ;
Koren, G .
DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (06) :1145-1149
[7]  
MCCALLUM RW, 1991, AM J GASTROENTEROL, V86, P135
[8]  
Moore K.L., 1988, DEV HUMAN
[9]  
PELLEGRINI E, 1994, MATERNAL FETAL TOXIC, P707
[10]  
SCHARDEIN JL, 1985, CHEM INDUCED BIRTH D, P452